Nava Health To Attend 4th Annual Benchmark Virtual Healthcare Conference
Nava Health To Attend 4th Annual Benchmark Virtual Healthcare Conference
COLUMBIA, MD / ACCESSWIRE / May 20, 2024 / Nava Health MD, Inc. ("Nava Health" or "Nava"), a leader in longevity, integrative and functional medicine, today announced that CEO Bernie Dancel will attend the 4th Annual Benchmark Healthcare House Call Virtual Investor Conference on Tuesday, May 21, 2024. Nava will participate in a fireside chat at 12:45pm ET and Mr. Dancel will be available for one-on-one meetings throughout the day.
领导寿命、综合和功能医学方面的领导者Nava Health MD,Inc. ("Nava Health" 或者 "Nava") 今天宣布 Nava 公司的首席执行官 Bernie Dancel 将于2024年5月21日星期二出席第四届 Benchmark Healthcare House Call 虚拟投资者大会。Nava 将在美国东部时间下午12:45参加一起虚拟会议并与 Mr. Dancel 进行一对一会议。
To register for the conference and access the fireside chat visit:
要注册参加会议并进入虚拟会议室,请访问:
In February 2024, Nava Health and 99 Acquisition Group, Inc. (Nasdaq:NNAG), a publicly traded special purpose acquisition company ("99 Acquisition"), announced that they had entered into a definitive merger agreement (the "Merger Agreement"). Upon closing the proposed transaction, 99 Acquisition will be renamed Nava Health, Inc. and expects to remain listed on the Nasdaq Stock Market under the ticker symbol "NAVA."
2024年2月,Nava Health 和99 Acquisition Group, Inc.(Nasdaq: NNAG),一家公开交易的特殊目的收购公司 ("99 Acquisition"),确定达成一项明确的合并协议 ("合并协议")。一旦完成拟议中的交易,99 Acquisition 将更名为 Nava Health, Inc. 并将继续在纳斯达克股票交易所下,标的符号将继续使用 "NAVA".
About Nava Health
关于 Nava Health
Nava Health is a vertically integrated, tech-enabled healthcare practice combining integrative, functional, preventive, and regenerative medicine. Nava's innovative medical practice uses a data-driven, personalized approach to optimize health and increase longevity. Nava provides each client with an individualized wellness roadmap tailored to their specific symptoms, medical needs, and personal goals. All client wellness roadmaps result from a proprietary diagnostic process, the "Nava Method," which utilizes data and specially designed software to create optimal personalized client outcomes. To learn more visit navacenter.com.
Nava Health 是一个纵向整合、技术驱动的医疗实践,综合综合、功能性、预防性和再生医学。Nava 富有创新性的医学实践采用数据驱动的、个性化的方法来优化健康和增加寿命。Nava 为每位客户提供一个个性化的健康路线图,为他们的症状、医疗需求和个人目标量身定制。所有客户健康路线图都是通过专有的诊断流程 "Nava 方法",利用数据和特别设计的软件来创建最佳的个性化客户结果。如需更多信息,请访问 navacenter.com。
About 99 Acquisition
关于 99 Acquisition
99 Acquisition Group, Inc. (Nasdaq: NNAG) is a blank check company that was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.
99 Acquisition Group, Inc.(Nasdaq: NNAG) 是一家空白支票公司,旨在与一家或多家企业或实体进行合并、股份交换、资产收购、股票购买、资本重组、重新组织或其他类似的业务组合。
Important Information about the Proposed Business Combination and Where to Find It
关于拟议的企业合并的重要信息和查询地址
This press release relates to a proposed transaction between 99 Acquisition and Nava Health. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed business combination, 99 Acquisition has filed a registration statement on Form S-4 containing a proxy statement/prospectus (the "Registration Statement") with the SEC, and 99 Acquisition and Nava Health intend to file other relevant materials with the SEC. The Registration Statement includes a proxy statement/prospectus to be distributed to holders of 99 Acquisition's common stock in connection with 99 Acquisition's solicitation of proxies for the vote by 99 Acquisition's stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to Nava Health's shareholders in connection with the proposed business combination. After the Registration Statement has been filed and declared effective, 99 Acquisition will mail a definitive proxy statement, when available, to its stockholders.
本新闻稿涉及 99 Acquisition 和 Nava Health 之间一项拟议交易。本新闻稿不构成出售或交换的要约,或购买或交换证券的要约,也不得在任何这些要约可能非法注册或依照任何这些接管中所述的证券法在任何辖区销售证券。有关拟议业务组合的详细信息,请与证券交易委员会 ("SEC") 地址为 Form S-4 的注册声明 ("Registration Statement") 以及99 Acquisition 和 Nava Health 意图在 SEC 提交其他相关材料。注册声明包括向99 Acquisition 普通股股东分发的代理声明 / 证券法律说明,涉及99 Acquisition 与 Nava Health 拟议交易的投票的许多事项,以及与拟议业务组合相关的向 Nava Health 的股东发行证券的招股说明书。在注册声明被提交并被宣布有效之后,99 Acquisition 将携带明确的代理声明 (如有) 发送给其股东。
Before making any voting or investment decision, investors and security holders and other interested parties are urged to read the Registration Statement, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about 99 Acquisition, Nava Health and the proposed business combination. Copies of these documents may be obtained free of charge at the SEC's website at www.sec.gov. The documents filed by 99 Acquisition with the SEC also may be obtained free of charge upon written request to 99 Acquisition at c/o 99 Acquisition Corp., 14 Noblewood Ct, Gaithersburg, MD 20878.
在做出任何投票或投资决策之前,投资者、证券持有人和其他感兴趣的各方应在它们变得可用之际仔细阅读 SEC 发布的注册声明、任何相关修订和其他文件的全部内容,因为这些文件将包含关于 99 Acquisition、Nava Health 和拟议业务组合的重要信息。这些文件的副本可免费获得 SEC 的网站 www.sec.gov。在提交书面请求给99 Acquisition c/o 99 Acquisition Corp.,14 Noblewood Ct,Gaithersburg,MD 20878 时,可以免费获得提交给 SEC 的99 Acquisition 文件的副本。99 Acquisition 及其董事和高管可能会形式上作为 SEC 规则下与拟议交易有关的证券持有人的代理人进行招股份额调查。有证券的持有人可通过阅读自行提供的信息以获得更多关于 99 Acquisition 的执行官和董事的名称、从属关系和兴趣方面的详细信息,在拟议交易时,这些信息是与 SEC 相关文件中的信息。关于 99 Acquisition 的董事和高管以及他们持有 99 Acquisition 普通股权以及与代理招股有关的参与者利益的其他信息通常可能与 99 Acquisition 的安排不同,这些信息来自注册声明。这些文件可以在 SEC 的网站 www.sec.gov 上免费获得。
Participants in the Solicitation
招标人
99 Acquisition and its directors and executive officers may be deemed participants in the solicitation of proxies from 99 Acquisition's securityholders with respect to the proposed transaction under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain executive officers and directors of 99 Acquisition in the solicitation by reading 99 Acquisition's Registration Statement and other relevant materials filed with the SEC in connection with the proposed transaction when they become available. Information about 99 Acquisition's directors and executive officers and their ownership of 99 Acquisition's common stock and other information regarding the interests of participants in the proxy solicitation, which, in some cases, may be different from those of 99 Acquisition's securityholders generally, is set forth in the Registration Statement. These documents can be obtained free of charge at the SEC's web site at www.sec.gov.
99 Acquisition 及其董事和高管可能会被假定为根据 SEC 规则在与拟议交易有关的证券持有人中募集方式的参与者。当在拟议交易时,证券持有人可以通过阅读 99 Acquisition 的注册声明和有关拟议交易的其他相关文件中的 SEC 资料来更加详细地了解 99 Acquisition 的某些执行官和董事的名称、从属关系和利益。在某些情况下,与代理招股的利益可能与 99 Acquisition 的证券持有人大体相同。关于 99 Acquisition 的董事和高管以及拟议交易中其利益位于一个名单中,该名单可在拟议交易的注册声明中获得相关信息。
Nava Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from 99 Acquisition's securityholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement for the proposed transaction.
Nava Health 及其董事和高管在与拟议交易有关的证券持有人募集方式中也可能被视为参与者。这些董事和高管的名称列表以及有关其在拟议交易中的利益的信息包含在拟议交易的注册声明中。
Non-Solicitation
禁止谋求
This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
本新闻稿不是针对任何证券的代理声明或代理、同意书或授权书。本新闻稿同时不构成出售或邀请出售任何证券的要约,也不得在任何国家或地区出售该证券,这些要约可能非法注册或依照任何这些地区的证券法律在这些地区进行销售。除符合1933年证券法第10条要求的招股说明书或其中的豁免所要求的材料外,不会出售证券。
Forward-Looking Statements
前瞻性声明
Certain statements made in this press release are "forward-looking statements" within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the parties' ability to close the proposed transaction, the anticipated benefits of the proposed transaction, and the financial condition, results of operations, earnings outlook and prospects of 99 Acquisition and/or the proposed transaction and may include statements for the period following the consummation of the proposed transaction. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.
此新闻稿中所作的某些声明是"前瞻性声明",根据美国1995年私人证券诉讼改革法案的安全港条款。这些声明涉及拟议交易的各方的能力、拟议交易的预期利益以及 99 Acquisition 和/或拟议交易的财务状况、运营结果、盈利前景和前景,并且可能包括在拟议交易完成后的时期的声明。此外,任何指向未来事件或情况的投资、展望或其他表述的声明,包括任何基本假设,都是前瞻性声明。前瞻性声明通常以"计划"、"相信"、"期望"、"预计"、"打算"、"展望"、"估计"、"预测"、"项目"、"继续"、"可能"、"可能"、"潜在"、"预测"、"应该"、"会"等类似的语言和表达式,但是不是使用这些语言的声明并不意味着该声明不是前瞻性声明。前瞻性声明基于99 Acquisition 和 Nava Health 管理层的当前预期,并本质上受到不确定性和情况的变化及其潜在影响的影响,并仅就声明日表达。无法保证未来的发展将是已经预期的。这些前瞻性声明涉及多个风险、不确定性或其他假设,可能导致实际结果或绩效与这些前瞻性声明所表达的实际结果或绩效有实质性不同,包括:与 Nava Health 的业务和策略有关的风险;由于未能获得 99 Acquisition 和/或 Nava Health 股东的批准或符合 Merger Agreement 规定的其他终止条件,无法完成拟议交易;现有 99 Acquisition 普通股的赎回数量;无法实现拟议交易预期的利益;在99 Acquisition 和 Nava Health 提交的注册声明中在 2023 年8月21日初次公开发行时涉及的"风险因素" 标题下的其他风险和不确定性;以及在 99 Acquisition 提交给 SEC 的其他文件中的风险和不确定性,这些文件表示并解决了其他重要的风险和不确定性,可能导致实际事件和结果与前瞻性声明所包含内容不同。前瞻性声明仅代表其发表时的情况。要求读者不要对前瞻性声明做出过度的依赖,Nava Health 和 99 Acquisition 不承担义务并不打算更新或修订这些前瞻性声明,是否由于新信息、未来事件或其他因素而导致。Nava Health 和 99 Acquisition 都没有确保 Nava Health、99 Acquisition 或合并后公司将实现其预期。
The forward-looking statements are based on the current expectations of the management of 99 Acquisition and Nava Health, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including: risks related to Nava Health's businesses and strategies; the ability to complete the proposed transaction due to the failure to obtain approval from the shareholders of 99 Acquisition and/or Nava Health or satisfy other closing conditions set forth in the Merger Agreement; the amount of any redemptions by existing holders of 99 Acquisition's common stock; the ability to recognize the anticipated benefits of the proposed transaction; other risks and uncertainties included under the header "Risk Factors" in the Registration Statement filed by 99 Acquisition and Nava Health, in the final prospectus of 99 Acquisition for its initial public offering dated August 21, 2023; and in 99 Acquisition's other filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Nava Health and 99 Acquisition assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Nava Health nor 99 Acquisition gives any assurance that Nava Health, 99 Acquisition or the combined company will achieve its expectations.
前瞻性声明基于99收购和Nava Health的管理层目前的预期,本质上存在不确定性和情况变化及其可能带来的影响,并仅限于此类声明之日。未来的发展未必如之前预期。这些前瞻性声明涉及许多风险、不确定因素和其他假设,可能会导致实际结果或业绩与这些前瞻性声明所表达或暗示的结果有着重大的区别,包括:Nava Health的业务和战略所涉及的风险;无法完成拟议交易,因为未能获得99收购和/或Nava Health的股东批准或满足并购协议中规定的其他闭锁条件;99收购普通股现有持有人的赎回金额;实现拟议交易预期收益的能力;另外在99收购和Nava Health注册声明书,设于2023年8月21日首次公开发行的99收购的最终招股说明书中包括的“风险因素”标题下包含的风险和不确定性,以及在99收购提交给美国证券交易委员会的其他备案。这些备案确定了及解决了其他重要的风险和不确定性,可能导致实际事件和结果与前瞻性声明所包含的不同。前瞻性声明仅在其发出之日起有效。读者应该谨慎对待前瞻性声明,Nava Health和99收购不承担任何义务或打算更新或修订这些前瞻性声明,无论是因为新信息、未来事件还是其他原因。Nava Health和99收购均未保证Nava Health、99收购或合并后的公司将实现其预期。
Investor Relations Contact
John Nesbett/Jennifer Belodeau
IMS Investor Relations
nava@imsinvestorrelations.com
投资者关系联系人
John Nesbett/Jennifer Belodeau
IMS投资者关系
nava@imsinvestorrelations.com
Media Contact
Suzanne Coblentz
Scoblentz@navacenter.com
媒体联系人
Suzanne Coblentz
Scoblentz@navacenter.com
SOURCE: Nava Health
来源: Nava Health